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ABSTRACT 
Objective: To develop and characterize a topical ophthalmic formulation containing chitosan-dextran sulfate nano particles (CDNs) for enhanced 
ocular bioavailability and stability of lutein. 
Methods: Lutein-loaded CDNs (LCDNs) were prepared by polyelectrolyte complexation employing oppositely charged polymers, chitosan and 
dextran sulfate. Effects of the polymer mass ratios, the total amount of polymers, and the amount of EDC and PEG400 on their physicochemical 
properties as well as the drug release profiles were investigated. The physicochemical stability of LCDNs dispersed in various ophthalmic vehicles 
and the accompanying microbial contamination were also evaluated. 
Results: LCDNs possessed a mean size of ~400 nm with a positive surface charge of+30 mV and entrapment efficiency up to 75%. Dissolution 
profiles followed a Higuchi’s square root model, indicating a diffusional release mechanism. LCDNs dispersed in Feldman ophthalmic buffer showed 
good physical stability with no microbial contamination. The chemical stability of lutein was significantly improved in LCDNs and further improved 
by the addition of antioxidant in the ophthalmic vehicle.  
Conclusion: The ophthalmic formulation containing LCDNs, developed in this work, has characteristics suitable for application in ocular surface 
drug delivery systems. 
Keywords: Chitosan, dextran sulfate, Nanoparticles, Ophthalmic vehicle, Lutein. 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
The cornea is the main route for topical ocular drug delivery. It also 
blocks ultraviolet radiation (UVA-UVB) from reaching the intraocular 
tissues. However, prolonged exposure to UV radiation generates 
reactive oxygen species (ROS) in the cornea, and its adnexa can 
exacerbate corneal inflammation and cause an adverse impact on 
anterior segment disorders including dry eye disease, keratoconus, 
and bullous keratopathy [1]. Oxidative stress, which refers to cellular 
or molecular damage caused by ROS, is pronounced in age-related 
disorders as a direct result of an imbalance between increasing ROS 
production and a concomitant decline in antioxidant defenses. Lutein 
is a major carotenoid found in the human retina, especially in the 
cellular layers and photoreceptor outer segments. Because of its 
lipophilicity, lutein partitions into membranes where it plays a crucial 
role as an antioxidant, especially against singlet oxygen generated by 
blue light. Furthermore, lutein absorbs maximally in the blue region of 
the spectrum and directly intercepts blue photons. It also provides 
protection against UV and ROS in other ocular structures, especially 
the uvea [2]. Thus, delivery of lutein to the cornea or anterior segment 
is potentially beneficial to treat oxidative stress associated with 
disorders such as Fuchs dystrophy and anterior uveitis [1]. Although, 
there are numerous oral preparations containing lutein, impact on 
anterior ocular structures seems to be limited [3]. In addition, very few 
studies have focused on the specific topical ophthalmic application of 
lutein [4]. It is of interest to note also that there are currently no lutein-
eye-drops products available in the market because of its limited 
stability. Lutein is a lipophilic molecule which is poorly soluble in 
water and notorious for its poor stability in solutions due to its 
susceptibility to oxidative degradation by light, heat and oxygen [5]. 
Thus, a formulation and delivery system which is able to maintain the 
reduced form during storage and promotes uptake are necessary for 
the clinical applications of this compound. 
Following topical application, drug persistence on the cornea surface is 
limited (half-life of 2-4 min) because of regular washing with lacrimal 
fluid and drainage into the nasolacrimal duct by blink-induced tear 
pumping [6]. In order to overcome these major drawbacks, various 
nanocarrier systems have been developed to improve ocular 
bioavailability [7-10]. We have recently reported on mucoadhesive 
chitosan-dextran sulfate nanoparticles (CDNs), a polymeric nanoparticle-
based delivery system, which is a potential candidate for ocular drug 
delivery because of prolonged corneal residence time and controlled 
drug release [8]. CDNs offer many advantages, including mild 
preparatory steps without using organic solvents, heat, and vigorous 
agitation [8]. The nanoparticles can be prepared by polyelectrolyte 
complexation, which can be achieved by merely mixing two oppositely 
charged polymers: chitosan (CS) and dextran sulfate (DS). As it has been 
highlighted before, CS is an ideal polymeric carrier because it is 
biocompatible, biodegradable, nontoxic, bioadhesive, and positively 
charged [8, 9]. The latter property is due to its positive charge, which 
promotes binding to the negatively charged mucopolysaccharides on the 
cornea. CS is soluble in most organic acidic solutions at pH<6.5. DS is also 
biocompatible but is negatively charged [11].  
Many studies have reported CDN formulations, but those focusing on 
topical ocular drug delivery are limited. Thus, in this study, we propose 
CDNs as a potential topical ocular delivery carrier for lutein. The main 
aim is to develop and characterize topical ophthalmic formulations 
containing mucoadhesive CDNs for controlled release and improved 
stability of lutein. The preparation of lutein loaded CDNs (LCDNs) under 
various conditions have been optimized to study their effect on 
physicochemical properties and an in vitro release profile of LCDNs. The 
suitable ophthalmic vehicle and stability profile of LCDNs at different 
storage temperatures were evaluated. Additionally, the microbial 
contamination after storage was determined. 
MATERIALS AND METHODS 
Materials 
Chitosan shrimp (CS; MW 30 kDa with 95% de acetylation) was 
obtained from Aqua premier Inc. (Bangkok, Thailand). Dextran sulfate 
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(DS, MW 500 kDa) and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) were purchased from Sigma-
Aldrich Chemie GmbH (Steinheim, Germany). Polyethylene glycol 400 
(PEG400) was purchased from Naming trading Co., Ltd (Bangkok, 
Thailand). Lutein (95% lutein extracted from marigold flower extract) 
was purchased from KEB Biotechnology Co., Ltd. (Beijing, China). 
Brain heart infusion agar (BHA) was obtained from Himedia 
Laboratories Pvt. Ltd (Mumbai, India). All other chemicals and 
reagents used were of analytical grade. Deionized (DI) water was used 
for the preparation of solutions and dispersion of nanoparticles. 
Preparation of lutein-loaded CDNs (LCDNs) 
LCDNs were prepared by the polyelectrolyte complexation 
technique [8]. For CS solution (1%, w/v), CS was dissolved in 1.75% 
(v/v) acetic acid. Lutein solution is (0.5% w/v) comprised of lutein 
dissolved in a mixture of dimethylsulfoxide, ethanol and Tween 80 
(49.5:50:0.5, v/v), and then mixed with CS solution. After the lutein 
solution was made, a DS solution (1%, w/v in DI water) and EDC 
(0.1%, w/v in DI water) were gently added to the CS-lutein solution 
with continuous homogenization at ~8000 RPM (Ultra-Turrax®, 
T25, IKA, German) at room temperature (RT) for 15 min. Finally, an 
aqueous solution of PEG400 was added and mixed. All solutions 
were sterilized separately with 0.2 μm membrane filter before 
mixing. Experimental parameters such as polymer mass ratio and 
total polymer mass, co-crosslinking agent, and stabilizing agent were 
varied. Lutein-free CDNs were prepared by the same procedure but 
without the addition of the lutein solution. All samples were 
prepared in the dark and produced in triplicates.  
Characterization of nanoparticles 
The mean particle size was measured by dynamic light scattering 
(DLS) using a ZetaPALS analyzer (Brookhaven Instruments 
Corporation, New York, US) with an aliquot diluted in DI water. The 
particle size distribution was reported by a polydispersity index 
(PI). Each sample was measured at 25 oC, a detection angle of 90o, 
and a wavelength of 659 nm in a 10 mm diameter cell. Each data 
point was an average of 10 runs, and data was subjected to 
cumulative analysis to obtain an average hydrodynamic diameter 
[12]. All experiments were carried out in triplicate.  
The surface charge on nanoparticles was measured by phase 
analysis of light scattering in the zeta potential (ZP) mode using 
ZetaPALS analyzer. Samples were prepared by re-dispersing the 
nanoparticles in DI water and measured at 25 oC. ZP was calculated 
from the measured electrophoretic mobility using the Smoluchowski 
approximation [13]. Each data point represents an average of 10 
runs. All experiments were carried out in triplicate. 
The entrapment efficiency (EE) of LCDNs was determined as follows: 
LCDNs were separated by centrifugation at 18 620 g for 30 min. 
Lutein was extracted from the sediment pellets by sonication with 
ethanol for 20 s at RT. The lutein in the supernatant obtained after 
subsequent centrifugation at 18 620 g for 30 min was analyzed using 
a UV-Vis spectrophotometer (446 nm). EE was calculated as 
[(Amount of lutein extracted) x 100/(Initial amount of lutein)]. EE 
was reported based on the mean of three independent trials. 
In vitro dissolution studies 
The shake-flask method was employed to evaluate the release 
profile of lutein from LCDNs. Since lutein possesses poor aqueous 
solubility, normal saline solution (pH 6.5) containing Tween 80 (1%, 
v/v) was used as a dissolution medium to provide sink condition. A 
known amount of LCDNs, which consists of lutein 25 µg/ml, was 
mixed with 10 ml of the dissolution medium and shaken at 100 RPM, 
employing a shaker at 34±0.5 °C in the dark. Samples (1 ml) of the 
dissolution medium were taken at predetermined time intervals of 
0.5, 1, 2, 3, 4, 5 and 6 h. The samples were then centrifuged at 18 620 
g for 30 min and the supernatant was assayed for the amount of 
lutein released using the UV-Vis spectrophotometer (446 nm). All 
dissolution experiments were carried out in triplicate. 
The impact of dispersion vehicles on physiochemical properties 
of LCDNs 
The formulation of LCDN prepared from the mass ratio of CS: DS at 
1:0.6 was dispersed in five different vehicles; normal saline solution 
(NSS, 0.9% w/v), Feldman ophthalmic buffer (FOB), chitosan 
solution (CS, 0.1% w/v), a mixture of CS in NSS (CN; CS/NSS ratio of 
0.14/1) and a mixture of CS in FOB (CF; CS/FOB ratio of 0.14/1). 
Benzalkonium chloride (BAC, 0.01% w/v), edetate disodium 
tetraacetic acid (EDTA, 0.01% w/v), and sodium metabisulfite (SM, 
0.2% w/v) were added in dispersion vehicles as preservatives, 
chelating, and antioxidant agents, respectively. All dispersion 
vehicles were sterilized by autoclaving at 121 °C and 15 psi for 20 
min. A known amount of LCDN, consist of lutein 25 µg/ml, was 
mixed with 25 ml of the dispersion vehicles. After storage at 37±0.5 
°C for 4 w in dark condition, the physiochemical stabilities of LCDNs 
in different vehicles were analyzed. The mean particle size, surface 
charge, pH and lutein remaining were monitored at 2-week 
intervals. All experiments were carried out in triplicate. 
Stability studies 
The formulation of LCDN-PE, prepared with the CS: DS mass ratio of 
1:0.6, PEG400 0.35% v/v, EDC 1 µg/ml, was dispersed in FOB 
solution with and without SM. LCDN-PE, 35 µg/ml of lutein content, 
was dispersed in an autoclaved-FOB solution under aseptic 
technique. For lutein solution, as a control, the same lutein content 
was also prepared with an autoclaved-FOB solution. Then, the 
samples were flushed with nitrogen gas and stored at 4 °C and RT in 
dark condition. After 6-month storage, the particle size, surface 
charge, and lutein remaining in nanoparticles were determined. The 
microbial contamination was also assessed by counting colonies 
after inoculating the sample onto brain-heart infusion agar (BHA), 
which was incubated at 37±0.5 °C for 7 d [14]. All experiments were 
carried out in triplicate. 
Statistical analysis 
The results are expressed as mean±standard deviation (SD). For all 
comparisons, statistical significance was tested by Student's t-test or 
one-way ANOVA followed by Tukey's post hoc test, and P<0.05 was 
considered statistically significant. 
RESULTS AND DISCUSSION 
Physicochemical properties of nanoparticles 
For the application of nanoparticles as topical ophthalmic 
administration, the size and surface charge of the particles are key 
parameters that influence the safety and efficacy of the formulation. 
Particle sizes exceeding 10 μm can scratch the highly innervated 
ocular surface during blinking and lead to irritation and patient 
discomfort [15, 16]. In addition, increasing resident time on the 
ocular surface enhances ocular drug bioavailability; nano-sized 
particles offer greater adhesive properties. Furthermore, the 
positively charged particles facilitate effective adhesion to the 
negatively charged pre-cornea surface via electrostatic interaction 
[17]. The following preparation conditions were designed to 
optimize these properties. 
CS/DS mass ratio: it is roughly equivalent to the charge ratio of CS to 
DS, which showed a strong effect on the mean particle size and 
surface charge of the nanoparticles, table 1A. As the mass ratio of the 
DS increased, the mean particle size decreased, and the positive 
surface charge decreased. Nevertheless, when the mass of the DS is 
equal and/or higher than the CS, the system showed precipitation 
and possessed negative surface charged particles. This was due to an 
excess of DS molecules accumulated on the surface of nanoparticles. 
The results suggest that the charge ratio and the mass ratio both 
play important roles in controlling the size and surface charge of 
nanoparticles. In addition, the particle size obtained from DLS was in 
agreement with SEM micrographs. The formulation factors showed 
no effect on the nanoparticles morphology. As shown in fig. 1, the 
nanoparticles observed under SEM showed spherical-shaped 
particles regardless of formulation factors.  
Polymer content: the total amount of polymers showed a critical 
effect on the mean particle size, but did not significantly affect the 
surface, as indicated in table 1B. Increasing the total polymer mass 
increased the mean particle size from 368 to 1,110 nm. This can be 
attributed to the higher viscosity of system compared to 
formulations with low polymer concentrations.  
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Co-crosslinking by EDC: this was investigated by varying the amount 
of EDC while keeping other factors constant, table 1C. The results 
showed that the formulation without EDC produced a lower mean 
particle size than those formed in its presence. As EDC is thought to 
increase the crosslinking density of polymer chains [18], which 
results in an increase in the particle size. 
Stabilizing agent by PEG400: finally, in contrast to EDC, varying the 
amount of PEG400, which was employed as a stabilizing agent, has 
only a minor effect on the mean particle size and surface charge, 
table 1D.  
In addition to particle size and surface charge, the drug entrapment 
efficiency was also affected by the processing parameters. An 
increase in the polymer mass ratio and total polymer mass resulted 
in increasing the lutein entrapment efficiency from 19% to 71%, as 
shown in table 1A and B. This is presumably due to a large number 
of nanoparticles being formed and greater polymer-drug 
interactions, which leads to increased entrapped lutein within the 
particles. As well, an increasing amount of PEG400 led to a sharp 
increase in entrapment efficiency, which could be observed up to 
75%, table 1D. This may be due to increasing interaction between 
lutein and PEG400 via hydrogen bonding. However, a decreasing 
trend in entrapment efficiency was observed when increasing the 
EDC concentration, table 1C. This is probably due to the high 
crosslinking density of the polymers increasing the diffusion 
resistance of lutein molecules from the polymer matrix to the 
medium. 
 
Fig. 1: Scanning electron micrographs of LCDNs prepared with 
0.35% v/v PEG400 and the CS: DS mass ratio of1:0.36 (A), and 
1:0.6 (B). Scale bar = 1 μm.
 
Table 1: Physicochemical properties of nanoparticles under various formulation factors 
Preparing conditions Mean size±SD 
(nm) 






A.  Mass ratio of CS: DS  
(charge ratio+/-) 
1:0.12 (7.64) 742±14 0.28±0.01 52±4 19±0 9±0 
1:0.36 (2.55) 600±14 0.27±0.01 47±2 55±9 27±4 
1:0.6 (1.53)  368±8 0.25±0.02 44±3 68±1 34±1 
1:1.0 (0.9) Precipitated Precipitated -19±1 Not determined Not determined 
1:1.6 (0.6) Precipitated Precipitated -36±2 Not determined Not determined 
B.  Total amount of polymers 
(mg/ml) 
0.6  467±12 0.25±0.01 43±2 55±2 27±1 
1.0 368±8 0.25±0.02 44±3 68±1 34±2 
1.2  491±11 0.26±0.01 43±6 66±3 33±3 
2.0 1,110±14 0.26±0.01 47±2 71±6 35±1 
C. EDC  (µg/ml) 0  368±8 0.25±0.02 44±3 68±1 34±1 
1  464±7 0.28±0.01 46±6 56±0 28±0 
3.5  469±7 0.27±0.01 44±1 52±1 26±1 
6.5  534±8 0.29±0.01 43±1 47±3 23±2 
D. PEG400 (%, v/v) 0  434±21 0.29±0.02 38±4 44±4 22±2 
0.25  426±7 0.25±0.02 46±1 55±2 28±1 
0.35  368±8 0.25±0.02 44±3 68±1 34±1 
1.00  551±4 0.26±0.02 41±3 75±2 38±1 
DS mass ratio (1:0.6) and PEG400 (0.35% v/v); D:CS:DS mass ratio(1:0.6). PI, poly dispersity index, EE; entrapment efficiency; SD, standard 
deviation, n=3, PI, poly dispersity index, EE; entrapment efficiency; SD, standard deviation, n=3. 
.  
 
In vitro release of lutein from LCDNs 
The in vitro release profiles of all formulations exhibited two release 
patterns: an initial burst release phase in the first 30 min followed by a 
slower release phase lasting for 6 h, fig. 2. The release profiles 
demonstrated that the initial burst release is attributed to the release of 
lutein bound to the nanoparticle surface [19, 20]. The slow release phase 
may be attributed to the swelling or degradation of the polymer, which 
leads to the formation of pores within the polymeric matrix. In order to 
investigate the mechanism of lutein release from LCDNs, the cumulative 
release profiles were analyzed by the three well-known kinetic models: 
zero order, first order, and Higuchi models. Based on the correlation 
coefficients (R2), the release profiles of all nanoparticles were best fitted 
to Higuchi’s square root model (R2=0.95-0.99). This indicates that lutein 
released from LCDNs in the slow release phase occurs via a diffusion-
controlled mechanism from the polymeric matrix. 
As shown in fig. 2A and 2B, the mass ratio and the total amount of 
polymers showed only a slight effect on drug release, presumably 
due to their similarity in size, 368-600 nm. However, the drug 
release rate was delayed when the total polymer mass was increased 
up to 2 mg/ml, presumably that the total polymer mass of 2 mg/ml 
could be increased tortuosity and decreased porosity in the polymer 
matrix of particles [21].  
Moreover, the particles larger than 1 µm can also be observed in this 
condition, thus, the drug release rate may also be partially attributed 
to the altered particle size. Based on the results, the formulations 
with a particle size smaller than 600 nm have a greater net surface 
area, which means that most of the associated drug would be at or 
near the particle surface thus leading to more rapid drug release. In 
the formulations with a particle size larger than 1 µm, the particles 
had a large core which allowed more of the drug to be encapsulated 
and to diffuse out slowly. 
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In addition to the polymer mass ratio and the total amount of 
polymer, the drug release rate was also affected by the amount of 
PEG400. As shown in fig. 2D, the drug release rate increased with 
increasing amounts of PEG400. The highest drug release rate was 
observed in the formulation containing 1% and 0.35% PEG400, 
while, the formulation without PEG400 showed the slowest release 
rate. In addition, in the formulations with PEG400, there was 
significant (P<0.05) difference in percentage drug released 
compared to the formulation prepared without PEG400. It could be 
postulated from these results that the role of PEG400 is achieved by 
two mechanisms. First, PEG400 might interact with lutein by 
hydrogen bonding, and some PEG400 might be localized at the 
particle surface. Thus, lutein that is adsorbed onto the nanoparticle 
surface and entrapped near the surface might be the reason for the 
initial burst release with in the first 30 min [20]. Second, PEG400 
might have been inserted inside the polymer matrix. As it is water-
soluble, it is easily leached out into the dissolution medium which 
leads to pore formation in the polymer matrix which enhances drug 
release [22]. Overall, the study demonstrates that the drug release 
rate is dependent on the amount of PEG400 in the formulation.  
Furthermore, the influence of EDC on the drug release rate was also 
studied in detail. Interestingly, the addition of EDC showed a 
significant effect on the drug release characteristics compared with 
non-EDC, as shown in fig. 2C. As the EDC was added, the drug release 
from the nanoparticles slowed down. This confirmed that EDC could 
increase the crosslinked density of the polymers as mentioned 
earlier. However, as the amount of EDC further increased from 1 to 
6.5 µg/ml, no significant change in the drug release rate was 
observed indicating that the drug release rate was controlled by the 
EDC, but large amounts of EDC are not required. 
 
 
Fig. 2: In vitro release profiles of lutein from LCDNs under various formulation factors; a polymer mass ratio (A), the total amount of 
polymer (B), amount of co-crosslinking agent (C) and amount of stabilizing agent (D). Error bars indicate SD for n = 3 
 
Dispersion vehicles 
The use of lutein in the ophthalmic administration is limited due to 
its poor aqueous solubility and susceptibility to oxidation. To 
overcome this limitation, the colloidal nanoparticles for the 
ophthalmic controlled delivery of lutein was developed and 
prepared by incorporating lutein into CDNs. We then dispersed the 
lutein-loaded CDNs in the ophthalmic vehicles. By these actions, we 
demonstrated that the physicochemical properties of the 
nanoparticles after the dispersion process are important parameters 
to optimize a suitable dispersion vehicle. Ideally, the dispersion 
vehicle must maintain the physiochemical properties of nano 
particles and also be nonirritating to the eyes. It must be 
appropriately formulated so that the suspended particles do not 
agglomerate into larger ones upon storage. Additionally, changes in 
the pH of the dispersion vehicle can affect the solubility and stability 
of drugs [23]. Consequently, it is important to minimize fluctuations 
in pH during storage. Thus, to optimize the suitable dispersion 
vehicle, the effect of various dispersion vehicles on physicochemical 
properties of LCDN was investigated in this study. As an initial step, 
the five main different vehicles were employed, namely N (NSS), F 
(FOB), C (CS), CN (CS+NSS) and CF (CS+FOB). NSS has been used 
commonly to prepare ophthalmic drops [23]; its salt concentration 
is similar to tears. CS solution has been reported as a novel vehicle 
for enhanced permeation and sustained release of drugs on the 
ocular surface [24]. Similar to NSS, FOB is commonly used to 
formulate ophthalmic drugs. It has been reported that FOB can also 
be used as a buffer with CS solutions for topical administration [25]. 
In addition, we used a simple formulation of LCDNs that consisted 
only of CS+DS+L so that potential interference of PEG400 and EDC 
was avoided. The lutein and nanoparticles were stored at 37oC for the 
accelerated stability test to avoid the rapid degradation of the lutein 
and to save time during the experiment. After the dispersion, the initial 
mean size value of the dispersed LCDN was approximately 434 nm and 
the surface charge was+38 mV in all ophthalmic vehicles. 
After storage at 37 oC for 2 w, all five dispersion vehicles induced 
significant aggregation of LCDN followed by precipitation (data not 
shown). The positive surface charge was reduced from+38 mV to 
approximately +20 mV, as shown in fig. 3A. This information indicates 
that even the LCDN had a high zeta potential value above +30 mV, 
which should enable good physical stability by electrostatic 
repulsion [21]. However, we noticed precipitation occurred during 
storage. This indicates that the stability of LCDN based on zeta 
potential is not enough. Another mechanism for colloidal 
stabilization is based on steric hindrance [21]. This mechanism is the 
driving force created by attaching macromolecules to the surface of 
the particle. In these situations, formulations of near zero zeta 
potential can be stable. Thus, a stabilizing agent should be added to 
LCDN formulations to enhance their stability. For this reason, the 
formulation LCDN with PEG400 and EDC, LCDN-PE, was prepared to 
improve their physical stability and for use instability studies. 
Furthermore, after 2 w of storage, the pH of all dispersion vehicles 
also tended to be more acidic, changing from 5.3 to 4.8, as shown in 
fig. 3B. This is consistent with the results of the chemical stability of 
lutein. As shown in fig. 3C, the lutein contents in nanoparticles of all 
dispersion vehicles were significantly decreased. However, the 
highest lutein remaining, up to 30%, was observed in FOB, while the 
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lowest were observed in NC, ~14%. This is consistent with the fact 
that FOB is widely used as a buffer in ophthalmic solutions because 
of its ability to maintain the pH level [24]. Therefore, FOB was 
employed as ophthalmic vehicles for further investigations. 
 
 
Fig. 3: The impact of various vehicles on physiochemical properties of LCDNs; surface charge (A), pH of the vehicle (B) and the percentage 
of lutein remaining (C). 
Error bars indicate SD for n = 3. (P<0.05; **Student's t test and*one-way ANOVA followed by Tukey's post hoc test) 
 
Stability studies 
LCDN-PE dispersed in dispersion vehicle, FOB, was used for stability 
studies. Since lutein degraded rapidly, SM was incorporated into the 
FOB as an antioxidant. The dispersed nanoparticles in FOB, with and 
without SM, were stored at 4oC and RT. Following 6 mo of storage, 
the results showed that the temperature did not have a significant 
effect on the physical properties of LCDN-PE. At both 4 °C and RT, 
the particle size and surface charge remained constant at ∼400-500 
nm and ∼30-40 mV, respectively (data not shown). The indicators of 
success related to the inclusion of PEG400 and EDC in the LCDN-PE 
formulation. PEG400 likely attaches to the particle surface and forms 
a coating, which creates steric hindrance and prevents particle-
particle contact [25]. EDC could act as a hardening agent by creating 
high crosslink density leading to a reduction in the degree of 
swelling, thereby preventing particle aggregation [26].  
 
Fig. 4: Percentage of lutein remaining in lutein solution and  
LCND-PE, dispersed in FOB in the absence and presence of 
antioxidant, after 6-month storage at 4 °C (A) and RT (B).  
Error bars indicate SD for n = 3." 
In addition to the physical stability of the nanoparticles, the chemical 
stability of the lutein is also an important issue. As shown in fig. 4, 
the lutein contents in solution form, both in the absence and 
presence of SM, decreased to 25% after being stored for 14 d and 
further degraded to 6% after 6 mo in all storage conditions. Since 
lutein has a long chain of conjugated carbon-carbon double bonds 
within its structure, it could be rapidly degraded by oxidation, 
especially when stored at high temperatures [5]. As expected, the 
colloidal LCDN-PE showed an excellent trend in lutein protection 
greater than the solution form (fig. 4). This indicates that the 
incorporation of lutein into nanoparticles could protect lutein from 
degradation. Especially when stored with SM at 4oC, the lutein 
content remaining in LCDN-PE was up to 93% and 76% after 2 and 
6-month storage, respectively, fig. 4A. On the other hand, the lutein 
content in the LCDN-PE without SM was decreased to 48% and 41% 
after 2 and 6-month storage, respectively, fig. 4A. At room 
temperature, the lutein content in the LCDN-PE without SM was 
degraded rapidly; only 12% was detected after 6-month storage, fig. 
4B. Interestingly, the lutein content of the LCDN-PE stored with SM 
was up to 86% after 14 d and 66% after 6 mo. These data clearly 
indicate that the stability of lutein in LCDN-PE could be further 
enhanced by the addition of SM. SM functions as an oxygen scavenger 
in order to eliminate dissolved oxygen from water and is used widely 
in the pharmaceutical industry to reduce or prevent oxidation [27, 28]. 
Furthermore, aseptic technique was used in the preparation of the 
sterile nanoparticles. Therefore, it is consistent that there was no 
microbial growth in BHA over a 7 d period during which it was 
checked for possible microbial contamination, as shown in fig. 5. 
 
 
Fig. 5: Optical micrographs of brain-heart infusion agar 
inoculated with lutein (A) and LCDN-PE (B), dispersed in FOB 
containing an antioxidant, after 7-day incubation 
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An ophthalmic formulation containing LCDNs for topical delivery of 
lutein was successfully developed. The various physicochemical 
properties of LCDNs, prepared by polyelectrolyte complexation, 
were greatly affected by the four compositional variables; CS: DS 
mass ratios, the total amount of polymers, and the concentrations of 
PEG400 and EDC. At optimal conditions, nanoparticles showed high 
entrapment, ∼68%, and possessed a spherical shape with a positive 
charge and mean diameter of ∼400 nm, which is unlikely to cause 
tear film impairment and ocular surface damage. Furthermore, this 
study demonstrates that the stability of lutein in an ophthalmic 
vehicle, FOB, containing LCDNs was significantly improved as 
compared to free lutein in the ophthalmic vehicles. The light and 
oxygen sensitivity of lutein was strongly reduced by incorporating 
lutein into CDNs. In addition, the stability of lutein in FOB containing 
LCDNs was further improved by adding sodium metabisulfite into 
the vehicle. The release kinetics of lutein from LCDNs could be fitted 
with Higuchi’s square root model and showed sustained release for 
longer than 6 h. Overall, this ophthalmic formulation containing 
LCDNs shows good potential for topical ocular application due to its 
mucoadhesives, ability to control drug release, high entrapment 
efficiency, and high physicochemical stability as well as being able to 
be prepared under mild and solvent-free conditions. 
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